Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer.
Karen Kelly(Cancer Research Center), Arta M. Monjazeb(University of California Davis Medical Center), Megan E. Daly(University of California Davis Medical Center), Leslie Garcia(UC Davis Health), E. Wiegner(Mercy General Hospital), Jonathan W. Riess(University of California Davis Medical Center), Amin Mirhadi(Cedars-Sinai Medical Center), Daiwen Chen(Sichuan Agricultural University), D.V. Eastham(David Grant USAF Medical Center), Frances Lara, Kurt A. Schalper(Yale University)
Cited by 12
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753